Assessment of carotid atherosclerosis in Egyptian chronic hepatitis C patients after treatment by direct-acting antiviral drugs

Egyptian Liver Journal

Table 5 Relation between IMT (at baseline and 6-month follow-up after initiation of anti-HCV therapy) and protocol of treatment

		Non-cirrhotic (no. = 26)			Child A (no. = 36)			Child B (no. = 18)			Test value^a	p-value^a
		Mean	± SD	Median	Mean	± SD	Median	Mean	± SD	Median	Test value^a	p-value^a
IMT	Baseline	1.18	0.46	0.95	1.17	0.32	1.04	1.46	0.61	1.42	4.75	0.093
IMT	6-month follow-up	0.95	0.39	0.76	0.97	0.35	0.90	1.06	0.49	0.88	2.61	0.271
p-value^b		< 0.001			< 0.001			0.001

p ≤ 0.05 is considered statistically significant; p ≤ 0.01 is considered highly statistically significant. ^aMann-Whitney U-test. ^bWilcoxon signed-rank test. SD Standard deviation, IMT Intima-media thickness. No significant difference between cases treated by double SOF/DAC therapy and cases treated by triple SOF/DAC/RBV therapy as regards carotid IMT at baseline and after 6-month follow-up. Meanwhile, there was significant decrease in carotid IMT at baseline compared to after 6-month follow-up in both double and triple therapies